<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03690739</url>
  </required_header>
  <id_info>
    <org_study_id>AGO-OVAR 2.32</org_study_id>
    <nct_id>NCT03690739</nct_id>
  </id_info>
  <brief_title>Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer</brief_title>
  <official_title>Trabectedin/PLD Versus Continuation of Platinum-based Chemo-therapy in Patients With Disease Stabilization and no Symptom Benefit Under Platinum-based Chemotherapy for Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGO Research GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, prospective, randomized, controlled, parallel group, multi-center&#xD;
      phase III trial to evaluate the Symptom Benefit Rate of trabectedin/PLD in patients with&#xD;
      recurrent ovarian cancer who achieve a stabilization of disease after 3 cycles of&#xD;
      platinum-based reinduction therapy and with no clinical benefit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 330 patients will be randomized in a 1:1 ration to the treatments specified&#xD;
      below:&#xD;
&#xD;
      Arm A - Platinum-based chemotherapy according to investigator's discretion Arm B - Pegylated&#xD;
      liposomal doxorubicin 30 mg/m² + Trabectedin 1.1 mg/m² (q3w)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient Recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">August 9, 2019</start_date>
  <completion_date type="Actual">March 3, 2021</completion_date>
  <primary_completion_date type="Actual">March 3, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom Benefit Rate</measure>
    <time_frame>from Baseline to 8 or 9 weeks after randomization, assessed at each visit</time_frame>
    <description>Proportion of patients achieving a symptom benefit defined as an at least 10-point improvement according to EORTC QLQ-OV28; EORTC QLQ-OV28 is a questionnaire regarding Quality of Life specialized for Ovarian Cancer with points from 1 till 4 for each of the 28 questions (1=not at all, 2=a little, 3=quite a bit, 4=very much). Points will be summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time until definitive deterioration (TUDD )</measure>
    <time_frame>from Baseline until 24 months after randomization, assessed up to 54 months at each visit</time_frame>
    <description>TUDD is defined as time from baseline until the first decrease in EORTC QLQ-C30 score ≥ 10 points (or 20 points) as compared at baseline; EORTC QLQ-C30 is a questionnaire regarding Quality of Life specialized for Cancer with points for each of the 30 questions (1=not at all, 2=a little, 3=quite a bit, 4=very much). Points will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>PFS is defined as time from randomization to disease progression according to RECIST v1.1, to death from any cause or to start of a new treatment (whichever occurs first), assessed up to 54 months</time_frame>
    <description>Progressive disease is based on investigator assessment using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) rate at 6 months</measure>
    <time_frame>PFS is defined as time from randomization to disease progression according to RECIST v1.1, to death from any cause or to start of a new treatment (whichever occurs first) after six months</time_frame>
    <description>Progressive disease is based on investigator assessment using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>from randomization until patients achieving complete response (CR) or partial response (PR) as best overall response, assessed up to 54 months</time_frame>
    <description>RR is based on investigator assessment using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Health Status</measure>
    <time_frame>from baseline to end of treatment, assessed up to 54 months at each visit</time_frame>
    <description>based on Quality of Life; EORTC QLQ-C30 and EORTC QLQ-OV 28 are questionnaires for Quality of Life with points for each of the 30 or 28 questions (1=not at all, 2=a little, 3=quite a bit, 4=very much). Points will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>OS is defined as the time from randomization to death from any cause, assessed up to 54 months</time_frame>
    <description>regular patient contact during the trila regarding life status</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Recurrent Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>platinum-based chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>According to the investigator's discretion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLD + Trabectedin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PLD 30 mg/m² + Trabectedin 1.1 mg/m² q21</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Administration according to investigator's discretion</description>
    <arm_group_label>platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Administration according to investigator's discretion</description>
    <arm_group_label>platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Administration according to investigator's discretion</description>
    <arm_group_label>platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLD</intervention_name>
    <description>Administration according to investigator's discretion</description>
    <arm_group_label>platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administration according to investigator's discretion</description>
    <arm_group_label>platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLD</intervention_name>
    <description>Administration 30 mg/m² q21</description>
    <arm_group_label>PLD + Trabectedin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectedin</intervention_name>
    <description>Administration 1.1 mg/m² q21</description>
    <arm_group_label>PLD + Trabectedin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Administration according to investigator's discretion</description>
    <arm_group_label>platinum-based chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females aged ≥ 18 years at time of signing informed consent form.&#xD;
&#xD;
          2. Histologically proven diagnosis of cancer of the ovary, the fallopian tube or primary&#xD;
             peritoneal cancer.&#xD;
&#xD;
          3. Measurable or non-measurable disease (according RECIST v1.1) or CA-125 assessable&#xD;
             disease (according GCIG criteria) or histologically proven diagnosis of relapse.&#xD;
&#xD;
          4. Platinum-treatment free interval (TFIp) &gt; 6 months prior to cycle 1 day 1 of&#xD;
             reinduction therapy.&#xD;
&#xD;
          5. Disease stabilization without remission or progression ac-cording to RECIST or GCIG&#xD;
             criteria after three cycles of platinum-based chemotherapy for recurrent disease.&#xD;
&#xD;
          6. Symptomatic disease at time of baseline abdominal/GI symptom scale score &gt;15 (EORTC&#xD;
             QLQ-OV28)&#xD;
&#xD;
          7. Completion of EORTC QLQ-OV28 at Baseline within 7 days prior to treatment start.&#xD;
&#xD;
          8. Patients should have received previously a taxane derivative.&#xD;
&#xD;
          9. ECOG performance status ≤ 2.&#xD;
&#xD;
         10. Life expectancy of at least 12 weeks.&#xD;
&#xD;
         11. Adequate bone marrow, renal and hepatic function defined as:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L&#xD;
&#xD;
               -  Platelet count ≥ 100 x 10^9/L&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               -  Serum creatinine ≤1.5 mg/dL (≤ 132.6 µmol/L) or creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
               -  Creatine phosphokinase (CPK) ≤ 2.5 x ULN&#xD;
&#xD;
               -  Serum aspartate aminotransferase (AST, SGOT) or alanine aminotransferase (ALT,&#xD;
                  SGPT) ≤ 2.5 x ULN (≤ 5 x ULN in the presence of liver metastases)&#xD;
&#xD;
               -  Alkaline phosphatase (ALP) ≤ 2.5 ULN&#xD;
&#xD;
               -  Serum bilirubin ≤ ULN&#xD;
&#xD;
               -  Albumin ≥ 25 g/l&#xD;
&#xD;
         12. Participation in an informed consent discussion with the appropriate trial-related&#xD;
             health care representative, full understanding of the implications and constraints of&#xD;
             the protocol, and provision of written informed consent prior to the commencement of&#xD;
             the trial-related procedures.&#xD;
&#xD;
         13. Geographically accessibility for treatment and follow-up.&#xD;
&#xD;
         14. For women of childbearing potential (WOCBP): agreement to remain abstinent (refrain&#xD;
             from heterosexual inter-course) or use a contraceptive method with a failure rate of &lt;&#xD;
             1 per-centage per year during the treatment period and for at least six months after&#xD;
             administration of the last dose of chemo-therapy. A woman is considered to be of&#xD;
             childbearing po-tential if she is postmenarcheal, has not reached a post-menopausal&#xD;
             state (≥ 12 continuous months of amenorrhea with no identified cause other than&#xD;
             menopause), and has not undergone surgical sterilization (removal of ovaries,&#xD;
             fal-lopian tubes, and/or uterus). Examples of contraceptive methods with a failure&#xD;
             rate of &lt; 1 percentage per year in-clude but are not limited to bilateral tubal&#xD;
             ligation and/or oc-clusion, male sterilization, and intrauterine devices, and nor-mal&#xD;
             and low dose combined oral pill plus male condom or Cerazette (desogestrel) plus male&#xD;
             condom. Cerazette is currently the only highly efficacious progesterone based pill.&#xD;
             The reliability of sexual abstinence should be evaluated in relation to the duration&#xD;
             of the clinical trial and the preferred and usual lifestyle of the patient. Periodic&#xD;
             abstinence (e.g., calendar, ovulation, symptothermal, or postovulation meth-ods) and&#xD;
             withdrawal are not acceptable methods of contra-ception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ovarian tumors of low malignant potential (e.g. borderline tumors).&#xD;
&#xD;
          2. Non-epithelial ovarian or mixed epithelial/non epithelial tumors (e.g. mixed Müllerian&#xD;
             tumors).&#xD;
&#xD;
          3. Patients with an objective response in terms of a partial or complete remission or&#xD;
             alternatively progressive disease ac-cording to RECIST or GCIG criteria after three&#xD;
             cycles of platinum-based reinduction chemotherapy.&#xD;
&#xD;
          4. Patients who have received previous radiotherapy for ovarian cancer.&#xD;
&#xD;
          5. History of congestive heart failure (NYHA classification &gt; 2, even if medically&#xD;
             con-trolled).&#xD;
&#xD;
          6. History of myocardial infarction within the last six months (documented or by&#xD;
             electrocardiogram).&#xD;
&#xD;
          7. History of atrial or ventricular arrhythmias.&#xD;
&#xD;
          8. Impaired liver function, hyperbilirubinemia, Serum creatinine &gt;1.5 mg/dL or &gt; 132.6&#xD;
             μmol/L or creatinine clearance &lt; 60 mL/min, left ventricular ejection fraction &lt; 45 %.&#xD;
&#xD;
          9. Severe active or uncontrolled infection.&#xD;
&#xD;
         10. Concurrent severe medical problems unrelated to malignancy, which would significantly&#xD;
             limit full compliance with the trial or expose the patient to extreme risk or&#xD;
             decreased life expectancy.&#xD;
&#xD;
         11. Patients with known hypersensitivity to the active substance or their compounds&#xD;
             related to trabectedin or PLD and patients with known hypersensitivity to one of&#xD;
             active substances or one of their compounds used in platinum-based chemotherapy as&#xD;
             described in the Summaries of Medicinal Products.&#xD;
&#xD;
         12. Patients with potential risks according to contraindication, warnings or interactions&#xD;
             of the used chemotherapeutic agents as stated in the SmPCs are not eligible for&#xD;
             participation in this trial.&#xD;
&#xD;
         13. Patients with contraindication regarding CT or MRI (only in case of contrast allergy)&#xD;
             are excluded.&#xD;
&#xD;
         14. Women of childbearing potential (WOCBP) not using highly effective contraceptive&#xD;
             methods.&#xD;
&#xD;
         15. Pregnancy or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felix Hilpert, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Mammazentrum am Krankenhaus Jerusalem, Hamburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Aschaffenburg-Alzenau</name>
      <address>
        <city>Aschaffenburg</city>
        <state>Bayern</state>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hochtaunus-Kliniken</name>
      <address>
        <city>Bad Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sozialstiftung Bamberg</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Bergisch Gladbach</name>
      <address>
        <city>Bergisch Gladbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis für Onkologie / Hämatologie</name>
      <address>
        <city>Bottrop</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenärzte Casparistraße</name>
      <address>
        <city>Braunschweig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evang. Kliniken Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agaplesion Markus Krankenhaus</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mammazentrum Hamburg am Krankenhaus Jerusalem</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Itzehoe</name>
      <address>
        <city>Itzehoe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ViDia Christliche Kliniken Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Memmingen</name>
      <address>
        <city>Memmingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken des Landkreises Neumarkt</name>
      <address>
        <city>Neumarkt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin, Onkologie und Hämatologie</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst von Bergmann</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agaplesion Diakonieklinikum Rotenburg</name>
      <address>
        <city>Rotenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thüringen Kliniken &quot;Georgius Agricola&quot;</name>
      <address>
        <city>Saalfeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>g.Sund Gyn. Kompetenzzentrum</name>
      <address>
        <city>Stralsund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus &quot;Johann Kentmann&quot;</name>
      <address>
        <city>Torgau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Dr. Horst Schmidt Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Symptom Benefit</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

